Colgate-Palmolive Company $CL Stock Position Lessened by Modera Wealth Management LLC

Modera Wealth Management LLC cut its holdings in shares of Colgate-Palmolive Company (NYSE:CL) by 6.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,662 shares of the company’s stock after selling 5,763 shares during the period. Modera Wealth Management LLC’s holdings in Colgate-Palmolive were worth $7,053,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in CL. State of Wyoming bought a new position in Colgate-Palmolive in the 3rd quarter valued at about $258,000. International Assets Investment Management LLC boosted its stake in Colgate-Palmolive by 171.5% during the 3rd quarter. International Assets Investment Management LLC now owns 10,000 shares of the company’s stock valued at $853,000 after purchasing an additional 6,317 shares during the last quarter. CHICAGO TRUST Co NA boosted its stake in Colgate-Palmolive by 39.9% during the 3rd quarter. CHICAGO TRUST Co NA now owns 7,197 shares of the company’s stock valued at $614,000 after purchasing an additional 2,053 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in Colgate-Palmolive by 12.2% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 1,359,738 shares of the company’s stock valued at $116,013,000 after purchasing an additional 147,800 shares during the last quarter. Finally, Partners Wealth Management LLC bought a new stake in Colgate-Palmolive during the 3rd quarter worth approximately $419,000. Institutional investors and hedge funds own 80.41% of the company’s stock.

Insider Buying and Selling at Colgate-Palmolive

In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 10,000 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $92.05, for a total value of $920,500.00. Following the completion of the transaction, the chief operating officer owned 64,901 shares in the company, valued at $5,974,137.05. This represents a 13.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Cahill sold 4,170 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $93.37, for a total value of $389,352.90. Following the sale, the director directly owned 28,373 shares of the company’s stock, valued at approximately $2,649,187.01. This represents a 12.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 175,191 shares of company stock worth $16,110,903 in the last quarter. 0.43% of the stock is currently owned by company insiders.

Key Stories Impacting Colgate-Palmolive

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.97 per share, above the roughly $0.92–$0.93 analyst consensus and up from $0.91 a year earlier. Revenue increased 4.6% year over year to $5.37 billion, also exceeding expectations. Colgate-Palmolive Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Organic sales growth, pricing, higher volumes and productivity initiatives supported the quarterly beat. Management raised its 2026 base-business EPS and gross-margin outlook, signaling better profitability despite cost pressures. Colgate Q3 Earnings Beat Estimates on Organic Sales and Pricing Gains
• Positive Sentiment: The company maintained its fiscal 2026 EPS outlook while improving its base-business profitability forecast. The stronger guidance likely explains the favorable investor reaction and elevated trading activity. Colgate-Palmolive Raises FY26 Base-Business EPS View
• Neutral Sentiment: Management narrowed its full-year sales-growth outlook, suggesting that pricing and productivity—not broad-based demand—remain important drivers of performance. Colgate-Palmolive Raises Profit Outlook Despite Weak US Demand
• Negative Sentiment: Weak U.S. demand and rising input costs remain risks. The earnings beat was strong, but investors may question how sustainable margin gains will be if consumer demand softens or cost inflation accelerates. Colgate-Palmolive Q3 Analysis

Colgate-Palmolive Price Performance

Shares of NYSE CL opened at $95.35 on Friday. Colgate-Palmolive Company has a twelve month low of $74.54 and a twelve month high of $99.33. The stock’s 50 day moving average price is $89.54 and its 200-day moving average price is $89.65. The company has a market capitalization of $76.01 billion, a PE ratio of 37.39, a PEG ratio of 4.61 and a beta of 0.33. The company has a quick ratio of 0.67, a current ratio of 1.03 and a debt-to-equity ratio of 13.82.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, October 30th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.34 billion. Colgate-Palmolive had a return on equity of 464.63% and a net margin of 9.68%. Colgate-Palmolive’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.91 earnings per share. On average, equities analysts anticipate that Colgate-Palmolive Company will post 3.89 EPS for the current year.

Colgate-Palmolive Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Tuesday, October 20th. This represents a $2.12 annualized dividend and a yield of 2.2%. Colgate-Palmolive’s payout ratio is currently 84.13%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CL. Evercore increased their price objective on Colgate-Palmolive from $100.00 to $101.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Colgate-Palmolive in a research report on Thursday, August 13th. Barclays upped their price target on Colgate-Palmolive from $80.00 to $87.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Morgan Stanley reiterated an “overweight” rating and set a $104.00 price target (up from $100.00) on shares of Colgate-Palmolive in a report on Monday, August 3rd. Finally, Bank of America lowered their price target on Colgate-Palmolive from $102.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, October 9th. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Colgate-Palmolive presently has a consensus rating of “Moderate Buy” and an average price target of $98.56.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.